News & Updates

Continued anti-VEGF use after disease control does not prevent nAMD recurrence
Continued anti-VEGF use after disease control does not prevent nAMD recurrence
06 Apr 2022

In patients with neovascular age-related macular degeneration (nAMD) who achieve functional and morphological disease stability, continuing treatment with antivascular endothelial growth factors (anti-VEGF) does not substantially reduce the risk of recurrence, reports a recent study.

Continued anti-VEGF use after disease control does not prevent nAMD recurrence
06 Apr 2022
Lipid levels a glaucoma risk?
Lipid levels a glaucoma risk?
05 Apr 2022 byAudrey Abella

Glaucoma appears to be associated with high total cholesterol and low high-density lipoprotein (HDL) levels, according to a systematic review and meta-analysis of observational studies.

Lipid levels a glaucoma risk?
05 Apr 2022
Low BP ups risk of open-angle glaucoma
Low BP ups risk of open-angle glaucoma
19 Mar 2022

Low levels of blood pressure (BP) appear to elevate the risk of developing open-angle glaucoma (OAG), reveals a recent US study. In addition, there is no evidence supporting a differential effect of medically treated and untreated low BP.

Low BP ups risk of open-angle glaucoma
19 Mar 2022
HDL3 cholesterol tied to primary open-angle glaucoma
HDL3 cholesterol tied to primary open-angle glaucoma
18 Mar 2022

A causal and specific association exists between high-density lipoprotein (HDL) 3 cholesterol and primary open-angle glaucoma (POAG), suggests a cross-sectional study, noting that dysregulation of cholesterol transport may contribute to the pathogenesis of POAG.

HDL3 cholesterol tied to primary open-angle glaucoma
18 Mar 2022